Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …

Background Monoclonal antibody treatment may prevent complications of coronavirus
disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal …

BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …

Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-…

Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized
with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment …

Interventions Patients were randomized to receive either open-label aspirin (n= 565), a
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
high-risk outpatients with mild to moderate COVID-19; however, only intravenous …

Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19
specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) …

IMPORTANCE The effectiveness of monoclonal antibodies (mAbs), casirivimab and imdevimab,
and sotrovimab, for patients with mild to moderate COVID-19 from the Delta variant is …